Amanda Azuma's Contact Details

Amanda Azuma's Company Details

Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academies of Science, Engineering and Medicine, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has more than 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with more than half of its academic departments ranked in the top 20 among all public medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has a total budget of $5 billion and an economic impact of nearly $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. The University of Maryland School of Medicine has three research institutes: the Institute of Human Virology (IHV), the Institute for Genome Sciences (IGS) and the Institute for Global Health (IGH). The Institute of Human Virology (IHV) was formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is a center of virology research. Robert C. Gallo, MD, is director of IHV. The Institute for Genome Sciences (IGS) was launched in 2007. It is an internationally recognized genomics research center at the University of Maryland School of Medicine. IGS investigators use genomic and bioinformatic tools to research genome function in health and diseases and work in interdisciplinary collaborations with biomedical investigators. IGS is led by Claire Fraser, PhD. Investigators at IGS work on Disease Ontology research, the Data Analysis and Coordination Center (DACC) for HMP, and other grants. IGS is one of the Genome Sequencing Center for Infectious Diseases (GSCID) centers designated by NIAID. The Institute for Global Health was established in 2015 with research sites in more than 14 different countries in South America, Africa and Southeast Asia. The Institute is dedicated to improving global health by conducting innovative research to develop new and improved ways of diagnosing, preventing, treating controlling and eradicating diseases of global impact. Current diseases of interest include malaria, Ebola, Zika and vaccine--preventable infectious diseases such as measles, cholera, typhoid, shigellosis, Escherichia coli, diarrheal diseases, influenza and others.